Boobalan Pachaiyappan
Stock Analyst at Roth Capital
(2.75)
# 2,188
Out of 4,996 analysts
21
Total ratings
38.1%
Success rate
2.43%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Boobalan Pachaiyappan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RNA Avidity Biosciences | Initiates: Buy | $62 | $42.95 | +44.35% | 1 | Sep 17, 2025 | |
| RVPH Reviva Pharmaceuticals Holdings | Reiterates: Buy | $7 → $3 | $0.30 | +916.95% | 2 | Aug 18, 2025 | |
| LGVN Longeveron | Maintains: Buy | $10 → $3 | $0.80 | +275.52% | 2 | Aug 15, 2025 | |
| GANX Gain Therapeutics | Maintains: Buy | $7 → $6 | $1.79 | +235.20% | 3 | Aug 13, 2025 | |
| CRVO CervoMed | Reiterates: Buy | $20 → $16 | $8.28 | +93.24% | 4 | Aug 12, 2025 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $31 → $12 | $7.09 | +69.25% | 2 | Jul 14, 2025 | |
| VRNA Verona Pharma | Reiterates: Buy | $92 → $116 | $106.69 | +8.73% | 2 | Jun 18, 2025 | |
| PYPD PolyPid | Maintains: Buy | $12 → $9 | $3.33 | +170.27% | 2 | Jun 18, 2025 | |
| CING Cingulate | Maintains: Buy | $12 → $11 | $3.81 | +188.71% | 2 | May 19, 2025 | |
| TRDA Entrada Therapeutics | Initiates: Buy | $29 | $5.80 | +400.00% | 1 | Dec 5, 2024 |
Avidity Biosciences
Sep 17, 2025
Initiates: Buy
Price Target: $62
Current: $42.95
Upside: +44.35%
Reviva Pharmaceuticals Holdings
Aug 18, 2025
Reiterates: Buy
Price Target: $7 → $3
Current: $0.30
Upside: +916.95%
Longeveron
Aug 15, 2025
Maintains: Buy
Price Target: $10 → $3
Current: $0.80
Upside: +275.52%
Gain Therapeutics
Aug 13, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $1.79
Upside: +235.20%
CervoMed
Aug 12, 2025
Reiterates: Buy
Price Target: $20 → $16
Current: $8.28
Upside: +93.24%
Capricor Therapeutics
Jul 14, 2025
Maintains: Buy
Price Target: $31 → $12
Current: $7.09
Upside: +69.25%
Verona Pharma
Jun 18, 2025
Reiterates: Buy
Price Target: $92 → $116
Current: $106.69
Upside: +8.73%
PolyPid
Jun 18, 2025
Maintains: Buy
Price Target: $12 → $9
Current: $3.33
Upside: +170.27%
Cingulate
May 19, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $3.81
Upside: +188.71%
Entrada Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $29
Current: $5.80
Upside: +400.00%